HOW MINDR WORKS
Start digitally. Treat clinically.
Our aim is to make the initial steps towards specialist care straightforward, while ensuring that clinical decisions remain in the hands of appropriately qualified healthcare professionals.
MAKE AN ENQUIRY
Complete our confidential online enquiry form and indicate the type of assessment or treatment pathway you wish to discuss.
INITIAL SCREENING
Where available, our patient coordination team will provide information about the relevant pathway and the next steps for assessment.
CLINICAL ASSESSMENT
An appropriately qualified clinician assesses your medical history, symptoms, current treatments and individual circumstances.
PERSONALISED TREATMENT PLANNING
Where clinically appropriate and legally available, your clinician may discuss treatment options, their risks, alternatives, costs and follow-up requirements.
TREATMENT & ONGOING CARE
Treatment may involve telehealth consultations, in-person appointments, specialist therapy sessions or prescribed pharmaceutical products, depending on the pathway.
Psychedelic dosing sessions, where authorised, require appropriate in-person clinical supervision.
Submitting an enquiry does not establish a doctor–patient relationship or guarantee an appointment, prescription or treatment.
MINDR PRODUCTS
PRECISION ORAL MEDICINE.
No smoking. No vaping.
MINDR intends to develop a premium range of oral cannabinoid pharmaceutical products, led by pastilles and gummies, with complementary capsule formulations.
Our proposed products combine carefully considered oral delivery formats with a recognisable pharmaceutical identity and an emphasis on consistent formulation, appropriate quality standards and professional dispensing.
The product strategy is deliberately focused on alternatives to inhaled cannabis.
Images depict proposed product concepts.
OUR PROPOSED PRODUCT FAMILY
MINDR SLEEP & REST
Oral cannabinoid formulation concepts intended for further clinical and commercial evaluation in sleep-related care.
MINDR PAIN & RELIEF
Proposed cannabinoid pastilles and capsules for consideration within clinician-managed chronic pain pathways.
MINDR CALM & BALANCE
Potential oral formulations for selected mental-health presentations, subject to clinical evidence, individual assessment and prescribing requirements.
MINDR PRECISION
Future research and development into controlled-dose oral formulations, including emerging psychedelic medicines where legally permitted and scientifically supported.
WHY ORAL FORMULATIONS?
Oral medicines offer an alternative for patients who do not wish to smoke or vaporise cannabis. Pastilles and capsules also allow a different approach to formulation, administration and product presentation.
MINDR sees an opportunity to develop a distinctive, professionally presented product family within the regulated pharmaceutical market.
Products, formulations, indications and availability are subject to development and regulatory requirements. The website must not display specific unapproved prescription-product promotions to the public.
PSYCHEDELIC-ASSISTED THERAPY
Specialist care in a regulated clinical setting.
Psychedelic-assisted therapy combines a prescribed medicine with structured clinical and psychological care.
It is substantially more involved than a conventional prescription appointment. Appropriate treatment requires screening, preparation, specialist oversight, supervised administration and follow-up.
OUR PROPOSED CLINICAL MODEL
- Assessment and suitability. Reviewing diagnosis, medical history, psychological needs, contraindications and alternative treatments.
- Preparation. Helping patients understand the proposed treatment, its limitations, risks and the clinical process.
- Supervised treatment. Where authorised, medicine administration occurs in an appropriately equipped clinical setting under qualified supervision.
- Follow-up and integration. Ongoing clinical review and psychological support as appropriate to the treatment plan.
MINDR's clinical model is intended to support safe, responsible access to emerging treatments within Australia's regulatory framework.
CHRONIC PAIN & MENTAL HEALTH
Recognising the connection between physical and mental health.
Persistent pain can affect sleep, mood, work, relationships and quality of life. Mental-health conditions can also complicate the experience and management of chronic pain.
MINDR intends to develop clinical services that recognise these overlapping needs rather than treating every symptom in isolation.
Our proposed pathways may include medical assessment, conventional treatments, specialist referrals and, where appropriate, consideration of prescribed oral cannabinoid medicines.
Medicinal cannabis is not suitable for everyone, and evidence varies considerably between conditions. Decisions about treatment must be based on individual assessment and current clinical guidance.
OUR CLINICIANS
Healthcare experience at the centre of MINDR.
MINDR's proposed clinical development is guided by medical professionals with experience across general medicine, clinical pharmacology, psychiatry and emerging mental-health treatments.
DR CHRISTOPHER CORNEY
Chief Executive Officer
Brisbane-based physician and medical leader, Dr Christopher Corney is a specialist in General Medicine and a Senior Lecturer at The University of Queensland. His interests include mental healthcare and the responsible development of psychedelic medicine in clinical practice.
DR MITCHELL McKEAN
Chief Medical Officer
Dr Mitchell McKean is a physician with experience in clinical pharmacology, toxicology and hospital medicine. His work brings a focus on clinical assessment, medication safety and medical governance to MINDR's proposed treatment services.
DR JULIAN DODEMAIDE
Psychiatrist | Authorised Prescriber
Dr Julian Dodemaide is a psychiatrist with a background in forensic psychiatry and professional training in psychedelic therapies. His expertise informs the development of specialist psychiatric treatment pathways.
Professional roles, current registrations, prescribing authorisations and actual service responsibilities must be confirmed before publication.
THE MINDR PLATFORM
More than a clinic.
MINDR is being developed as an integrated clinical and pharmaceutical business, with distinct activities that support the broader future of mental healthcare.
MINDR CLINIC
Specialist mental-health assessment and proposed psychedelic-assisted therapy services, with appropriate clinical governance and patient support.
MINDR PRODUCTS
A proposed range of oral cannabinoid pharmaceutical formulations, including pastilles, gummies and capsules.
MINDR PHARMACY
A specialist pharmacy and dispensing strategy intended to support appropriately authorised medicine supply through licensed operations or partners.
MINDR WHOLESALE
A proposed business-to-business pharmaceutical ordering platform connecting authorised medicine suppliers, pharmacies and healthcare providers.
MINDR D1
A proposed clinician-controlled precision medicine dispensing device designed to explore secure, monitored medication delivery. The D1 remains a development-stage concept.
HOLLOGRAF INSTITUTE
Professional education and workforce development through the International College of Psychedelic Medicine, with introductory learning opportunities for qualified healthcare professionals.
MINDR D1
Precision medicine. Greater clinical control.
Introducing the proposed MINDR D1 platform.
MINDR D1 is a development-stage concept for clinician-controlled medication dispensing and monitoring.
The proposed technology is intended to explore how secure access controls, connected systems and precise dosing mechanisms could support future pharmaceutical treatment models.
Potential applications may include selected oral medicines and future research into emerging therapeutic compounds, subject to technical validation and regulatory requirements.
THE DEVELOPMENT VISION
- Clinician-managed dispensing permissions.
- Secure patient access controls.
- Connected monitoring capabilities.
- Potential integration with future treatment protocols.
MINDR D1 is not currently presented as a commercially available or approved medical device.
Concept artwork, not a commercial product.
HOLLOGRAF INSTITUTE
Building the professional workforce for psychedelic medicine.
The development of psychedelic medicine requires appropriately trained healthcare professionals, sound clinical governance and a strong understanding of emerging evidence.
Hollograf Institute is developing introductory courses and professional education through the International College of Psychedelic Medicine.
The proposed education offering is intended for psychiatrists, psychologists, medical practitioners and other appropriately qualified professionals interested in understanding the field and exploring opportunities for responsible participation.
EDUCATION FOCUS
- Introduction to psychedelic medicine.
- Clinical and scientific foundations.
- Australian regulatory pathways.
- Models of care and clinical implementation.
- Professional opportunities and emerging research.
Courses and enrolment dates will be announced when available. Participation does not confer prescribing authority or professional accreditation unless expressly stated and verified.
INTERNATIONAL VISION
Australian foundations. International ambitions.
MINDR's initial clinical strategy is centred on Australia, where regulated pathways exist for appropriately authorised psychiatric prescribing of MDMA and psilocybin for specified conditions.
Over time, MINDR intends to investigate opportunities for international patient coordination, specialist healthcare partnerships, oral pharmaceutical products and potential treatment infrastructure in other jurisdictions.
This includes preliminary consideration of international mental-healthcare and medical-tourism opportunities, subject to clinical, commercial and regulatory feasibility.
International patients interested in Australian services may register an enquiry. Treatment eligibility, travel arrangements and continuity of care require individual assessment.
FREQUENTLY ASKED QUESTIONS
Common questions
You can submit an enquiry about specialist assessment. Psychedelic-assisted therapy is not available on demand and requires independent clinical assessment, appropriate prescribing authorisation and a suitable treatment setting.
Australia has a regulated pathway under which specifically authorised psychiatrists may prescribe MDMA for PTSD in defined circumstances. Access is restricted and subject to applicable requirements.
Appropriately authorised psychiatrists may prescribe psilocybin for treatment-resistant depression under Australia's regulated pathway. Eligibility must be assessed individually.
MINDR is developing a medicinal cannabis pathway focused on oral formulations. Current service availability must be confirmed before an appointment or prescription can be offered.
MINDR's proposed branded product strategy focuses on oral medicines rather than dried flower, smoking or vaping products.
A medicinal cannabis consultation does not establish eligibility for psychedelic-assisted therapy. Any referral or treatment decision requires a separate specialist clinical assessment.
International enquiries are welcome. Suitability, treatment availability, travel, regulatory requirements and follow-up arrangements must be assessed before any appointment is confirmed.
You can discuss your treatment interests with a clinician, but prescribing decisions are based on clinical suitability, available evidence and legal requirements.
The product images shown on this website are proposed concepts. Availability will be confirmed only when appropriate commercial and regulatory arrangements are in place.
BOOK AN ASSESSMENT / MAKE AN ENQUIRY
YOUR NEXT STEP STARTS HERE.
Tell us what you're looking for.
Whether you're seeking information about specialist mental-health assessment, chronic pain care, medicinal cannabis or psychedelic-assisted therapy, you can start with a confidential enquiry.
Our team will explain the available next steps and whether an appropriate assessment pathway may be available.
START YOUR MINDR ENQUIRY
Full name — required
Email address — required
Mobile number — required
Location — State / country
Preferred contact method — Email / Phone
What would you like to enquire about?
- PTSD / MDMA-assisted therapy assessment
- Treatment-resistant depression / psilocybin assessment
- Chronic pain consultation
- Medicinal cannabis / oral medicines
- Mental-health consultation
- International patient enquiry
- General enquiry
Preferred appointment format
- Telehealth assessment
- In-person appointment, where available
- Please advise
Additional information (optional)
Please provide a brief description of your enquiry. Do not include detailed medical records or highly sensitive information in this initial form.
I understand that submitting this enquiry does not guarantee an appointment, prescription or treatment. I have read the Privacy Policy and consent to MINDR contacting me about my enquiry.
Thank you for contacting MINDR. Your enquiry has been received. Our team will review your request and contact you using your preferred contact method. Please do not use this form for urgent medical assistance. If you are in immediate danger, call 000 in Australia.
WORK WITH MINDR
Professional & commercial enquiries
MINDR welcomes enquiries from qualified healthcare professionals, pharmacies, pharmaceutical suppliers, researchers and prospective commercial partners interested in responsible development of emerging mental-health treatments.
Enquiry categories
- Clinical partnerships.
- Pharmacy and dispensing partnerships.
- Pharmaceutical supply and wholesale.
- Professional education.
- Research and technology.
- Corporate and investment enquiries.
MINDR
RETHINKING THE MIND.
Specialist mental healthcare. Psychedelic medicine. Pharmaceutical innovation.
Home · Treatments · Products · How It Works · Our Clinicians · About · Contact
Privacy Policy · Terms of Use · Medical Disclaimer · Complaints & Feedback
MINDR Pharmaceuticals Pty Ltd · mindr.help
© 2026 MINDR Pharmaceuticals Pty Ltd. All rights reserved.
Medical disclaimer: Information on this website is general in nature and does not replace medical advice, diagnosis or treatment. Services and medicines are subject to clinical suitability, legal requirements and availability. Product imagery may depict concepts under development.
Home · Treatments · Products · How It Works · Our Clinicians · About · Contact
MINDR
RETHINKING THE MIND.
A new approach to mental health, chronic pain and emerging medicines.
MINDR is developing an integrated specialist healthcare platform bringing together mental-health consultations, psychedelic-assisted therapy, medicinal cannabis treatment pathways and pharmaceutical innovation.
Our approach combines qualified medical professionals, individual clinical assessment and evidence-informed treatment options for people seeking specialist care.
From initial digital enquiries and clinical screening to specialist assessment and appropriate treatment, MINDR aims to make navigating complex mental-healthcare pathways clearer and more accessible.
Treatment availability depends on clinical suitability, applicable prescribing requirements and service readiness.
Specialist mental healthcare. A broader vision.
Mental-healthcare needs are diverse. So are the treatment pathways that may be appropriate.
MINDR is being developed around the principle that patients should have access to informed clinical assessment, appropriate treatment options and coordinated ongoing care.
Our specialist interests include psychedelic-assisted therapy, conventional psychiatric and psychological care, and prescribed oral cannabinoid medicines for eligible patients.
Behind our clinical activities is a broader pharmaceutical business focused on medicine dispensing, oral formulations, professional education and future treatment technology.
Start digitally. Treat clinically.
OUR TREATMENT PATHWAYS
Exploring appropriate care, together.
MINDR's proposed clinical services span three principal treatment pathways.
PSYCHEDELIC-ASSISTED THERAPY
MDMA-assisted therapy for PTSD
Australia has established a regulated pathway under which appropriately authorised psychiatrists may prescribe MDMA for post-traumatic stress disorder in defined circumstances.
MINDR intends to support eligible patients through specialist assessment, treatment planning, preparation, supervised therapy and follow-up care.
This is a specialist treatment pathway, not an on-demand medicine service. Eligibility and access depend on independent psychiatric assessment, applicable authorisations and clinical arrangements.
PSILOCYBIN-ASSISTED THERAPY
A specialist pathway for treatment-resistant depression
Psilocybin may be prescribed by appropriately authorised psychiatrists for treatment-resistant depression under Australia's regulated Authorised Prescriber framework.
MINDR intends to develop clinical pathways incorporating psychiatric assessment, psychological preparation, supervised treatment and appropriate post-treatment support.
Not everyone experiencing depression will be suitable for this approach. A specialist assessment is essential.
MEDICINAL CANNABIS
Oral medicines for eligible patients
MINDR is developing a medicinal cannabis service focused on oral formulations, including pharmaceutical pastilles, gummies and capsules.
Our intended clinical focus includes chronic pain and selected mental-health or sleep-related presentations where a qualified prescriber considers medicinal cannabis appropriate, having regard to the evidence, risks and available alternatives.
MINDR's proposed branded product range deliberately excludes dried flower, smoking products and vaping devices.